Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Fine-Tuning Liver Glucose Metabolism

By Biotechdaily staff writers
Posted on 30 Jun 2006
Researchers have traced the biochemical mechanism responsible for modulating the uptake, release, and synthesis of glucose by the liver.

Previous findings had shown that hormonal and nutrient regulation of glucose synthesis in the liver was controlled by modulation of the transcriptional coactivator protein PGC-1-alpha. In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) learned that PGC-1-alpha resides in a multi-protein complex containing the acetyltransferase GCN5. Fine-tuning of glucose metabolism depends on inactivation of PGC-1-alpha by this enzyme and its subsequent sequestering away from the genes it was normally meant to activate.

This mechanism was demonstrated experimentally by using an adenovirus vector to implant the gene for GCN5 into the livers of a group of starved mice. Normally such animals are actively releasing glucose into the blood, but results published in the June 2006 issue of Cell Metabolism showed that glucose release in these genetically engineered animals was significantly reduced.

"These results show that changing GCN5 is sufficient to control the sugar balance in mice,” explained senior author Dr. Pere Puigserver, assistant professor of cell biology at Johns Hopkins University. "Therefore, GCN5 has the potential to be a target for therapeutic drug design in the future. Understanding the ways that energy production and use are controlled is crucial to developing new drugs and therapies.”



Related Links:
Johns Hopkins University

Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.